Avadel Pharmaceuticals Secures Favorable Court Ruling for LUMRYZ

An announcement from Avadel Pharmaceuticals ( (AVDL) ) is now available.

Avadel Pharmaceuticals has announced a favorable court ruling upholding the FDA’s approval of its drug LUMRYZ, a once-at-bedtime treatment for narcolepsy. This decision reinforces LUMRYZ’s clinical superiority over Jazz Pharmaceuticals’ twice-nightly oxybate products, enabling continued market availability and exclusivity for Avadel. LUMRYZ, approved for both adults and pediatric patients, offers a significant advancement in patient care by minimizing sleep disruption, marking a major milestone for Avadel’s commercial growth.

Find detailed analytics on AVDL stock on TipRanks’ Stock Analysis page.